Lymphadenopathy in a patient at high risk for malignancy: what is the first-line diagnostic test?

Lymphadenopathy in a patient at high risk for malignancy: what is the first-line diagnostic test?

• A. CT scan
• B. Excisional biopsy
• C. Fine-needle aspiration
• D. Blood tests

Answer: (C)

When a patient at high risk for malignancy presents with lymphadenopathy, the first-line diagnostic test is fine-needle aspiration of the affected node. This approach gives a quick, minimally invasive way to obtain cells for cytologic analysis, helping determine whether the enlargement is malignant, metastatic, infectious, or reactive. It can be done outpatient, with low risk and cost, and the results typically guide the next steps—whether that’s imaging for staging, targeted additional biopsies, or moving toward treatment planning. If the aspirate is nondiagnostic or if lymphoma is strongly suspected, an excisional biopsy may then be needed to evaluate tissue architecture and provide a definitive diagnosis, but it is more invasive and not the initial step. Imaging like CT can assist with staging but does not replace tissue diagnosis, and routine blood tests are not diagnostic for malignancy.

When a patient at high risk for malignancy presents with lymphadenopathy, the first-line diagnostic test is fine-needle aspiration of the affected node. This approach gives a quick, minimally invasive way to obtain cells for cytologic analysis, helping determine whether the enlargement is malignant, metastatic, infectious, or reactive. It can be done outpatient, with low risk and cost, and the results typically guide the next steps—whether that’s imaging for staging, targeted additional biopsies, or moving toward treatment planning. If the aspirate is nondiagnostic or if lymphoma is strongly suspected, an excisional biopsy may then be needed to evaluate tissue architecture and provide a definitive diagnosis, but it is more invasive and not the initial step. Imaging like CT can assist with staging but does not replace tissue diagnosis, and routine blood tests are not diagnostic for malignancy.